These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 5927944)

  • 1. Prostate carcinoma and multiple primary malignancies. Study of a family and 109 consecutive prostate cancer patients.
    Lynch HT; Larsen AL; Magnuson CW; Krush AJ
    Cancer; 1966 Dec; 19(12):1891-7. PubMed ID: 5927944
    [No Abstract]   [Full Text] [Related]  

  • 2. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadruple primary malignancies.
    HANKINS EA; MILLER AC
    JAMA; 1962 Mar; 179():896-8. PubMed ID: 13904347
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics and colon cancer.
    Lynch HT; Guirgis H; Swartz M; Lynch J; Krush AJ; Kaplan AR
    Arch Surg; 1973 May; 106(5):669-75. PubMed ID: 4349634
    [No Abstract]   [Full Text] [Related]  

  • 5. Identical genetic profiles in primary and metastatic bladder tumors.
    Summers JL; Falor WH; Ward RM; Fiorito J; Brezler MR; Abreu AJ
    J Urol; 1983 Apr; 129(4):827-8. PubMed ID: 6573516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of epigenetic modifiers on the treatment of prostate and bladder cancer.
    Zhang Z; Karam J; Frenkel E; Sagalowsky A; Hsieh JT
    Urol Oncol; 2006; 24(2):152-60. PubMed ID: 16520279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five separate malignancies in one patient all apparently successfully treated.
    Ostrowski MJ
    Br Med J; 1975 Dec; 4(5999):736-7. PubMed ID: 1212582
    [No Abstract]   [Full Text] [Related]  

  • 8. Preoperative scanning: evaluation for metastatic disease in carcinoma of the breast, lung, colon, bladder, and prostate.
    Smalley RV; Malmud LS; Ritchie WG
    Semin Oncol; 1980 Dec; 7(4):358-69. PubMed ID: 7008200
    [No Abstract]   [Full Text] [Related]  

  • 9. [Association of adenocarcinoma of the prostate with transitional carcinoma of the bladder].
    de Boccard GA; Chatelanat F; Graber P
    Helv Chir Acta; 1985 Sep; 52(3-4):533-4. PubMed ID: 4066384
    [No Abstract]   [Full Text] [Related]  

  • 10. [One molecule, two faces. Epithelial loss of cell adhesion molecule CEACAM1 activates angiogenesis in bladder and prostate cancer].
    Tilki D; Oliveira-Ferrer L; Kilic N; Friedrich MG; Stief CG; Ergun S
    Urologe A; 2007 Sep; 46(9):1128-34. PubMed ID: 17605118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
    REITEMEIER RJ; MOERTEL CG; BLACKBURN CM
    Cancer Chemother Rep; 1964 Jan; 34():21-3. PubMed ID: 14116215
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitance of urogenital with lymphoid and intestinal malignancies: more than a coincidence.
    Shabtai F; Lask D; Kimchi D; Hart J; Halbrecht I
    Urol Int; 1985; 40(3):145-7. PubMed ID: 4040290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimizing treatment of advanced urologic malignancies].
    Heidenreich A; Ohlmann CH; Ozgür E; Pfister D; Sahi D; Thüer D; Engelmann UH
    Urologe A; 2007 Sep; 46(9):1278-84. PubMed ID: 17628781
    [No Abstract]   [Full Text] [Related]  

  • 14. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer.
    Naimi B; Latil A; Berthon P; Cussenot O
    Int J Cancer; 2000 Aug; 87(3):455-6. PubMed ID: 10897055
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
    Mai KT; Yazdi HM; Farmer J
    Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers.
    Yu Y; Yang JL; Markovic B; Jackson P; Yardley G; Barrett J; Russell PJ
    Clin Cancer Res; 1997 Jul; 3(7):1045-9. PubMed ID: 9815782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families.
    Dong C; Hemminki K
    Int J Cancer; 2001 Apr; 92(1):144-50. PubMed ID: 11279618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial urinary bladder cancer.
    Purtilo DT; McCarthy B; Yang JP; Friedell GH
    Semin Oncol; 1979 Jun; 6(2):254-6. PubMed ID: 482963
    [No Abstract]   [Full Text] [Related]  

  • 19. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.
    Esrig D; Freeman JA; Elmajian DA; Stein JP; Chen SC; Groshen S; Simoneau A; Skinner EC; Lieskovsky G; Boyd SD; Cote RJ; Skinner DG
    J Urol; 1996 Sep; 156(3):1071-6. PubMed ID: 8709310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour suppressor genes in urinary tract oncology.
    Brewster SF; Gingell JC; Brown KW
    Br J Urol; 1992 Dec; 70(6):585-90. PubMed ID: 1336697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.